Latest California Healthline Stories
Sin barreras, los precios de algunos medicamentos existentes se han disparado, incluso cuando han caído drásticamente en otros países. Los nuevos medicamentos tienen precios enormes, respaldados por el lobby y el marketing.
Community With High Medical Debt Questions Its Hospitals’ Charity Spending
Pueblo, Colorado, residents have higher-than-average medical debt, while the city’s two tax-exempt hospitals provide relatively low levels of charity care.
Journalists Talk Madera Hospital Bankruptcy Woes and Savings for Covered California Enrollees
California Healthline senior correspondent Bernard J. Wolfson and Fresno Bee reporter Melissa Montalvo discuss community efforts to save a bankrupt hospital from liquidation. California Healthline contributing radio correspondent Stephanie O’Neill Patison reports how lawmakers won additional Covered California subsidies.
North Carolina Hospitals Have Sued Thousands of Their Patients, a New Report Finds
An analysis of court records by the state treasurer and Duke researchers finds Atrium Health, originally a public hospital system, accounted for almost a third of the legal actions against North Carolina patients over roughly five years.
An Arm and a Leg: How a Surprise Bill Can Hitch a Ride to the Hospital
The No Surprises Act has helped rein in out-of-network medical bills, but ground ambulances are a costly exception. Hear why this service can still hit patients with big bills and what to do if you get one.
Proposed Rule Would Make Hospital Prices Even More Transparent
A Biden administration proposal would help standardize the data on prices that hospitals provide to patients, increase its usefulness to consumers, and boost enforcement. Previous rules gave hospitals too many loopholes.
Your Exorbitant Medical Bill, Brought to You by the Latest Hospital Merger
After decades of unchecked mergers, health care is the land of giants, with huge medical systems monopolizing care in many cities, states, and even whole regions of the country. This decreases patient choice, impedes innovation, erodes quality of care, and raises prices. And federal regulators have been slow to act.
New Alzheimer’s Drug Raises Hopes — Along With Questions
Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.
What One Lending Company’s Hospital Contracts Reveal About Financing Patient Debt
Within two years of North Carolina’s public university system going into business with AccessOne to finance patients’ payment plans, nearly half of its patients were in loans that charged interest. As federal scrutiny increases on lenders, California Healthline is sharing that contract and others obtained through public records requests.
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.